Takeda joins WIPO Re:Search

Friday, September 18, 2015

Takeda Pharmaceutical, based in Osaka, Japan, is participating in WIPO Re:Search, a consortium to accelerate R&D of new drugs, vaccines and diagnostics for neglected tropical diseases, malaria and tuberculosis. WIPO Re:Search’s aim is to advance product development through greater collaboration, while making concrete contributions to strengthen the foundations of healthcare in developing countries.

[Read More]

Sanford Consortium, Takeda partner in $10M innovation alliance

Thursday, June 11, 2015

The Sanford Consortium for Regenerative Medicine in La Jolla, Calif., and Takeda Pharmaceutical have agreed to establish a $10 million, five-year innovation alliance that would advance each organization’s research missions. Specifically, translational research and proof-of-concepts research projects will be identified and generated with an ultimate goal of delivering innovative therapeutic products to patients.

[Read More]

New Synexus board gears up for expansion through organic growth and acquisition

Wednesday, June 10, 2015

Following the completion of the management buyout of Synexus, the new board confirms its intention to expand the footprint of the company through organic growth and acquisition. Synexus, a multi-national company dedicated to the recruitment and running of clinical trials at its own research centers across the globe, intends to become a major player in the U.S., continue to expand its existing network of sites in Europe and Africa and develop a presence in Asia and South America.

[Read More]

TransCelerate Biopharma turns three

Monday, June 1, 2015

The name alone excites many in clinical research. It’s the first—or so far best promoted—consortium consisting only of high-level people from big biopharmaceutical companies, each vowing to be deeply “pre-competitive” with one another while trying to rework some of the redundant and wasteful practices endemic to clinical research.

[Read More]